Tag Archives: Congress

Affordable Care Act, Biosimilar, Health Insurance

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

Posted on by Dr. Randy
28
Nov

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down

Continue reading →
Specialty Drug

VA Extending Hepatitis C Therapy

Posted on by John Santilli

VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]

Continue reading →